Enhancement and Availability

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

High-Concentration

High-Concentration Biologics Are Redefining Subcutaneous Delivery

Pharma's Almanac

Drug Delivery

Intracellular Delivery: Reaching Targets Beyond the Cell Surface

David Alvaro, Ph.D.

Pharma's Almanac

LAI Formulation

The Formulation Science Behind Extended Drug Release

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Drug–Device

Designing Formulations Around Devices Rather Than Vice Versa

Pharma's Almanac

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

LAIs

The Long View: How Extended-Duration Therapies Are Reshaping Patient Care

Pharma's Almanac